The first recipients of funding under the UK government's £500 million Sovereign AI programme have been announced, intended ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

The FDA has extended its review of a new subcutaneous formulation of Sanofi's multiple myeloma therapy Sarclisa – which has ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...

MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees ...

As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of using AI for drug discovery ...

Too many patient access strategies stop at “script filled”. But this approach is ultimately short-sighted, failing to build ...

The Trump administration has extended the duration of a pilot programme to provide access to obesity drugs through Medicare, ...

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...

Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...

In the pharmaceutical and healthcare sectors, where precision is paramount and human lives are directly impacted, these ...

A combination regimen for kidney cancer treatment based on MSD's Welireg has failed a phase 3 trial, denting the company's ...